# Adjuvant Chemotherapy Combined With Camrelizumab for IIA -IIIA NSCLC Patients

Source: https://onco.cc/trials/nct05825443/  
OnCo record `nct05825443` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of camrelizumab in lung cancer, run by Nanfang Hospital, Southern Medical University, now recruiting.

## Summary

Adjuvant Chemotherapy Combined With Camrelizumab for IIA -IIIA NSCLC Patients is a phase 2, interventional study registered as NCT05825443 by Nanfang Hospital, Southern Medical University, with a registry enrolment figure of 57 participants, started 2023-04-10 and due to reach its primary completion in 2026-04-01. Interventions recorded: Camrelizumab. Conditions listed: Immunotherapy; Chemotherapy. Primary outcome: Two-years disease free survival (2y-DFS). Lung eligibility wording from the registry: "For patients with non-small cell lung cancer who have undergone surgical resection, the TNM stage after surgery is IIA-IIIA;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: PANORAMA
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05825443
- Phase: 2
- Setting: Efficacy and Safety of Postoperative Adjuvant Chemotherapy Combined With Camrelizumab for Patients With IIA -IIIA Non-small Cell Lung Cancer：a Phase II , Single-arm Clinical Study
- Sponsor: Nanfang Hospital, Southern Medical University
- Enrolled: 57

## Sources

- ClinicalTrials.gov NCT05825443: https://clinicaltrials.gov/study/NCT05825443

## Connected records

- cancers: [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05825443.json